There were 19 press releases posted in the last 24 hours and 161,508 in the last 365 days.

Worldwide Fallopian Tube Cancer Therapeutics Market Insights (2019-2023): Increasing Number of Drug Approvals Spurring Market Growth

/EIN News/ -- Dublin, Aug. 14, 2019 (GLOBE NEWSWIRE) -- The "Global Fallopian Tube Cancer Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Array of strong drug approvals

One of the major growth factors of the global fallopian tube cancer therapeutics market is the increasing number of drug approvals in recent years. Various pharmaceutical vendors started conducting research on novel targeted therapies. These targeted therapies have an affinity toward inhibiting the overexpression of a specific target and increasing the immunity of the body toward cancerous cells. The market also witnesses the presence of various other targeted therapies in the late stages of the pipeline for the treatment of fallopian tube cancer.

Two of the heavily researched targeted therapies for the indication are PD-1 inhibitors and PD-L1 inhibitors. The studies conducted in the early stages of clinical trials for fallopian tube cancer suggest that these drugs show a significant reduction in the tumor while providing long-term relief. Such factors will lead to the expansion of the global fallopian tube cancer therapeutics market at a CAGR of over 8% during the forecast period.

Use of nanotechnology for effective treatment

Various researchers are conducting studies on developing a nanoparticle-based drug delivery system, which could help the drug in reaching the target site without reducing its bioavailability. They increase the half-life of the drug in the circulatory system and have the ability to bypass the barriers caused by the blood tissue, specific target tissues, and cells. They increase the onset of the drug while providing a prolonged therapeutic action.

These factors help nanoparticles to be an effective drug delivery for the administration of chemotherapy drugs. as it helps in overcoming drug resistance mechanisms in various tumors while enhancing the drug penetration into the tumor. This development is expected to have a positive impact on the overall market growth.

Market Dynamics

Also, our global fallopian tube cancer therapeutics market report also looks at factors such as growing attention toward women's health, an array of strong drug approvals, strategic alliance.

However, difficulty in diagnosis, the strong threat from substitutes, high cost of treatment may hamper the growth of the fallopian tube cancer therapeutics industry over the forecast period.

Segment Analysis

The fallopian tube cancer therapeutics market analysis considers sales from both targeted therapy and chemotherapy. The analysis also considers the sales of fallopian tube cancer therapeutics in APAC, Europe, North America, South America, and MEA.

In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as heavy research on targeted therapies, high efficacy of the same will play a significant role in the targeted therapy segment to maintain its market position.

Competitive Landscape

With the presence of a few major players, the global fallopian tube cancer therapeutics market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading fallopian tube cancer therapeutics manufacturers, that include:

  • AstraZeneca PLC
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Pfizer Inc.

Also, the fallopian tube cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Comparison by product
  • Targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

  • Growing research on regenerative therapies
  • Advent of treatment vaccines for cancer
  • Use of nanotechnology for effective treatment

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca PLC
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/r/49rbup

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Primary Logo

Distribution channels: Culture, Society & Lifestyle, Science


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.